Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 3, 2015, Pages 358-367

  Witte, Michael M ^a   Foster, Norman L ^b   Fleisher, Adam S ^c   Williams, Monique M ^d,e   Quaid, Kimberly ^f   Wasserman, Michael ^g   Hunt, Gail ^h   Roberts, J Scott ⁱ   Rabinovici, Gil D ^j   Levenson, James L ^k   Hake, Ann Marie ^a,l   Hunter, Craig A ^a   Van Campen, Luann E ^a   Pontecorvo, Michael J ^m   Hochstetler, Helen M ^a   Tabas, Linda B ^a   Trzepacz, Paula T ^a,l  

^a ELI LILLY AND COMPANY   (United States)

^b Brain Institute   (United States)

^c BANNER ALZHEIMER S INSTITUTE   (United States)

^d IPC The Hospitalist Company Inc   (United States)

^e VITAS Innovative Hospice   (United States)

^f Indiana University   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h National Alliance for Caregiving   (United States)

ⁱ UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m AVID RADIOPHARMACEUTICALS   (United States)

more..

Author keywords

Alzheimer's disease; Amyloid ; Bioethics in neurology; Biomarkers; Dementia; Diagnostic use; Mild cognitive impairment; Positron emission tomography

Indexed keywords

EID: 84940179269     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.06.006     Document Type: Article

References (59)

1. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010, 68:319-329.
2. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283.
3. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurol 2011, 10:424-435.
4. Klunk W.E. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011, 32(Suppl 1):S20-S36.
5. Johnson K.A., Minoshima S., Bohnen N.I., Donohoe K.J., Foster N.L., Herscovitch P., et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013, 54:476-490.
6. Johnson K.A., Minoshima S., Bohnen N.I., Donohoe K.J., Foster N.L., Herscovitch P., et al. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society of Nuclear Medicine and Molecular Imaging. Alzheimers Dement 2013, 9:e106-e109.
7. Waldorff F.B., Buss D.V., Eckermann A., Rasmussen M.L., Keiding N., Rishøj S., et al. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: The multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ 2012, 345:e4693.
8. Thies W., Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9:208-245. Alzheimer's Association.
9. Classifications: International classification of diseases, 10th revision 2014, World Health Organization, Available at: http://www.who.int/classifications/icd/en/index.html. Accessed June 4, 2014.
10. Diagnostic and statistical manual of mental disorders, Fifth Edition, Text Revision 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC.
11. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
12. Beach T.G., Monsell S.E., Phillips L.E., Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012, 71:266-273.
13. Beach T.G., Sue L.I., Walker D.G., Sabbagh M.N., Serrano G., Dugger B.N., et al. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: Implications for amyloid imaging. J Alzheimers Dis 2012, 28:869-876.
14. Haneuse S., Larson E., Walker R., Montine T., Sonnen J. Neuropathology-based risk scoring for dementia diagnosis in the elderly. J Alzheimers Dis 2009, 17:875-885.
15. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
16. Gay B.E., Taylor K.I., Hohl U., Tolnay M., Staehelin H.B. The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. J Nutr Health Aging 2008, 12:132-137.
17. Newell K.L., Hyman B.T., Growdon J.H., Hedley-Whyte E.T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999, 58:1147-1155.
18. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:270-279.
19. Matthews B.R., Miller B.L. Alzheimer's disease. The behavioral neurology of dementia 2009, 56-73. Cambridge University Press, New York.
20. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
21. Frisoni G.B., Bocchetta M., Chételat G., Rabinovici G.D., de Leon M.J., Kaye J., et al. Imaging markers for Alzheimer disease: Which vs how. Neurology 2013, 81:487-500.
22. Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol 2014, 13:614-629.
23. Hogervorst E., Barnetson L., Jobst K.A., Nagy Z., Combrinck M., Smith A.D. Diagnosing dementia: Interrater reliability assessment and accuracy of the NINCDS/ADRDA criteria versus CERAD histopathological criteria for Alzheimer's disease. Dement Geriatr Cogn Disord 2000, 11:107-113.
24. Johnson H., Bouman W.P., Pinner G. On telling the truth in Alzheimer's disease: A pilot study of current practice and attitudes. Int Psychogeriatr 2000, 12:221-229.
25. Carpenter B.D., Xiong C., Porensky E.K., Lee M.M., Brown P.J., Coats M., et al. Reaction to a dementia diagnosis in individuals with Alzheimer's disease and mild cognitive impairment. J Am Geriatr Soc 2008, 56:405-412.
26. Lecouturier J., Bamford C., Hughes J.C., Francis J.J., Foy R., Johnston M., et al. Appropriate disclosure of a diagnosis of dementia: Identifying the key behaviours of "best practice". BMC Health Serv Res 2008, 8:95.
27. Bradford A., Kunik M.E., Schulz P., Williams S.P., Singh H. Missed and delayed diagnosis of dementia in primary care prevalence and contributing factors. Alzheimer Dis Assoc Disord 2009, 23:306-314.
28. Grossberg G.T., Christensen D.D., Griffith P.A., Kerwin D.R., Hunt G., Hall E.J. The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: Recommendations of an expert consensus panel. Prim Care Companion J Clin Psychiatry 2010, 12. PCC.09cs00833.
29. Schneider J.A., Bennett D.A. Where vascular meets neurodegenerative disease. Stroke 2010, 41(10 Suppl):S144-S146.
30. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013, 12:357-367. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.
31. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
32. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132(Pt 5):1310-1323.
33. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., et al. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt11):2837-2844.
34. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., et al. Longitudinal assessment of beta-amyloid and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
35. Highlights of prescribing information: Amyvid (florbetapir F 18 injection) for intravenous use 2014, Available at: http://pi.lilly.com/us/amyvid-uspi.pdf. Accessed June 4, 2014.
36. Vizamyl (flutemetamol F 18 injection): Highlights of prescribing information 2013, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203137s002lbl.pdf. Accessed June 4, 2014.
37. Highlights of prescribing information. Neuraceq (florbetaben F 18 injection), for intravenous use 2013, Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf. Accessed June 4, 2014.
38. Klein E.P., Kaye J. Dementia specialists and early adoption. J Alzheimers Dis 2013, 33:445-450.
39. Fagan A.M. CSF biomarkers of Alzheimer's disease: Impact on disease concept, diagnosis, and clinical trial design. Adv Geriatr 2014, 2014:14. Article ID 302712.
40. Hinton L., Franz C., Friend J. Pathways to dementia diagnosis: Evidence for cross-ethnic differences. Alzheimer Dis Assoc Disord 2004, 18:134-144.
41. Doraiswamy P.M., Sperling R.A., Johnson K., Reiman E.M., Wong T.Z., Sabbagh M.N., et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 2014, 19:1044-1051. AV45-A11 Study Group.
42. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012, 72:578-586. Alzheimer's Disease Neuroimaging Initiative.
43. Kawas C.H., Greenia D.E., Bullain S.S., Clark C.M., Pontecorvo M.J., Joshi A.D., et al. Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ study. Alzheimers Dement 2013, 9:199-203.
44. Grundman M., Pontecorvo M., Salloway S.P., Doraiswamy P.M., Fleisher A.S., Sadowsky C.H., et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord 2013, 27:4-15. AV45-A17 Study Group.
45. Ossenkoeple R., Prins N.D., Pijnenburg Y.A., Lemstra A.W., van der Flier W.M., Adriaanse S.F., et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013, 9:414-421.
46. Connell C.M., Roberts J.S., McLaughlin S.J., Carpenter B.D. Black and white adult family members' attitudes toward a dementia diagnosis. J Am Geriatr Soc 2009, 57:1562-1568.
47. Witte M.M., Barnes J., Lingler J., Agronin M., Hochstetler H., Healey K., et al. Testing the use of standardized scripts for disclosing "hypothetical/mock" amyloid PET scan results to nondemented cognitively-impaired patients and their care partners. Alzheimers Dement 2013, 9(Suppl):P131-P132.
48. Karnieli-Miller O., Werner P., Aharon-Peretz J., Sinoff G., Eidelman S. Expectations, experiences, and tensions in the memory clinic: The process of diagnosis disclosure of dementia within a triad. Int Psychogeriatr 2012, 24:1756-1770.
49. Dementia: Ethical issues 2009, Nuffield Council on Bioethics, Available at: http://nuffieldbioethics.org/project/dementia/. Accessed June 4, 2014.
50. Fischer M.A., Stedman M.R., Lii J., Vogeli C., Shrank W.H., Brookhart M.A., et al. Primary medication non-adherence: Analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010, 25:284-290.
51. Nowrangi M.A., Rao V., Lyketsos C.G. Epidemiology, assessment, and treatment of dementia. Psychiatr Clin North Am 2011, 34:275-294.
52. Leuzy A., Gauthier S. Ethical issues in Alzheimer's disease: An overview. Expert Rev Neurother 2012, 12:557-567.
53. Storandt M., Morris J.C. Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch Neurol 2010, 67:1364-1369.
54. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012, 11:1006-1012.
55. Trevena L.J., Zikmund-Fisher B.J., Edwards A., Gaissmaier W., Galesic M., Han P.K., et al. Presenting quantitative information about decision outcomes: A risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak 2013, 13(Suppl 2):S7.
56. Lee S.M., Roen K., Thornton A. The psychological impact of a diagnosis of Alzheimer's disease. Dementia (London) 2014, 13:289-305.
57. Roberts J.S., Christensen K.D., Green R.C. Using Alzheimer's disease as a model for genetic risk disclosure: Implications for personal genomics. Clinical Genetics 2011, 80:407-414.
58. Roberts J.S., Dunn L., Rabinovici G. Amyloid imaging, risk disclosure, and Alzheimer's disease: Ethical and practical issues. Neurodegener Dis Manag 2013, 3:219-229.
59. Mitsis E.M., Bender H.A., Kostakoglu L., Machac J., Martin J., Woehr J.L., et al. A consecutive case series experience with [18F] florbetapir PET imaging in an urban dementia center: Impact on quality of life, decision making, and disposition. Mol Neurodegener 2014, 9:10.